[-] Show simple item record

dc.contributor.authorMeza, Jameseng
dc.contributor.authorWeaver, Kareneng
dc.contributor.authorMartin, Sandra I.eng
dc.date.issued2013eng
dc.description.abstractEvidence-Based Answer: Men with symptomatic androgen deprivation who have had clinically curative treatment for organ-confined prostate cancer may have symptomatic improvement with testosterone replacement therapy. (Strength of Recommendation [SOR]: C, based on two small case series.) There are no studies evaluating the risk of cancer recurrence in patients receiving testosterone replacement therapy. However, testosterone replacement therapy may be associated with increased prostate-specific antigen (PSA) levels. (SOR: C, based on one case report.) Some men discontinue therapy because their symptoms do not improve. (SOR: C, based on a small case series.)eng
dc.identifier.urihttp://hdl.handle.net/10355/39057eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionClinical Inquiries, 2013 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri--Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesAmerican family physician, 88, no. 08 (October 15, 2013)eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.titleTestosterone Therapy and Risk of Recurrence After Treatment for Prostate Cancereng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record